(NASDAQ: AKRO) Akero Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Akero Therapeutics's revenue in 2024 is $0.On average, 3 Wall Street analysts forecast AKRO's revenue for 2026 to be $2,586,364,734, with the lowest AKRO revenue forecast at $1,453,039,198, and the highest AKRO revenue forecast at $3,644,364,178. On average, 1 Wall Street analysts forecast AKRO's revenue for 2027 to be $6,533,328,124, with the lowest AKRO revenue forecast at $6,533,328,124, and the highest AKRO revenue forecast at $6,533,328,124.
In 2028, AKRO is forecast to generate $20,897,079,418 in revenue, with the lowest revenue forecast at $20,897,079,418 and the highest revenue forecast at $20,897,079,418.